P831 Clinical factors associated with severity in patients with Inflammatory Bowel Disease in Brazil (On Behalf of GEDIIB)

Froes, R.(1)*;Andrade , A.R.(2);Faria, M.A.G.(3);Parra, R.S.(4);Zaltman, C.(5);Souza, H.S.P.(5);Santos, C.H.M.D.S.(6);Bafutto, M.(7);Quaresma , A.B.(8);Santana , G.O.(2);Rafael Luís Luporini, R.L.(9);Lima Junior , S.F.D.(10); Miszputen, S.J.(11);Souza , M.M.D.(12);Herrerias , G.S.P.(13); Kaiser Junior, R.L.(3);Nascimento , C.R.D.(1);Féres , O.(4);Barros , J.R.D.(13);Guimarães , C.D.S.(14);Sassaki , L.Y.(13); Saad-Hossne, R.(15);

(1)Gastromed, Department of Gastroenterology and Endoscopy, Rio de Janeiro, Brazil;(2)Bahia State University UNEB, Department of Life Science, Salvador, Brazil;(3)Kaiser Hospital Dia, Department of Proctology, São José do Rio Preto, Brazil;(4)Ribeirão Preto Medical School- University of São Paulo, Department of Surgery and Anatomy, Ribeirão Preto, Brazil;(5)Universidade Federal do Rio de Janeiro- Hospital Universitário Clementino Fraga Filho, Department of Medical Clinic, Rio de Janeiro, Brazil;(6)Hospital Universitário Maria Aparecida Pedrossian, Department of Surgery, Campo Grande, Brazil;(7)Instituto Goiano de Gastroenterologia, Department of Gastroenterology, Goiânia, Brazil;(8)UNOESC, Department of Health Sciences, Joaçaba, Brazil;(9)Universidade Federal de São Carlos, Department of Medicine, São Carlos, Brazil;(10)Hospital Universitário João de Barros Barreto UFPA, Department of Proctology, Belém, Brazil;(11)São Paulo Federal University, Department of Gastroenterology, São Paulo, Brazil;(12)Hospital Universitário Júlio Müller, Department of Surgical Clinic, Cuiabá, Brazil;(13)São Paulo State University Unesp- Medical School, Department of Internal Medicine, Botucatu, Brazil;(14)GEDIIB, Department of National Registry of IBD patients, Salvador, Brazil;(15)São Paulo State University Unesp- Medical School, Departament of Surgery, Botucatu, Brazil;


Brazil has shown an increase in Inflammatory Bowel Disease (IBD) cases. GEDIIB (Brazilian Organization of Crohn's Disease and Colitis) established a data platform to create a national registry of IBD patients. The study aimed to characterize the profile of IBD patients and identify clinical factors associated with IBD severity.


A cohort study was conducted between Jul/20 and Aug/22. Data obtained from medical records and/or directly from patients were registered via REDCap. Local institutional review boards approved the study protocol. We designed a population-based risk model aimed at stratifying severe disease based on one or more outcome variables: previous hospitalization, surgery, and biologics. Univariate and bivariate analyses and Poisson modeling were used.


A total of 1,179 patients were included: 600 (51%) with ulcerative colitis (UC), 568 (48%) with Crohn's Disease (CD), and 11 (0.9%) with indeterminate colitis. The mean age was 34.4±14.7y, 59% female, 73% Caucasian, and 85.3% non-smoker. Regarding the initial symptoms, 42% presented diarrhea, 38% abdominal pain, and 20% weight loss. The age of IBD symptom onset ranged from 1-87 years (32.3±14.4). According to the Montreal classification of CD, A1: 5%, A2: 63%, A3: 32%; L1: 29.7%, L2: 14.3%, L3: 41.2%, B1: 32%, B2: 26.7%, B3: 11.3%; perianal 15.5%. In UC, 46.3% presented pancolitis and 30% left-sided colitis. Only 3.9% were malnourished, 30.9% were overweight, and 18% were obese. The main extraintestinal manifestations were rheumatologic (21%). Regarding medical treatment, 68.1% of the patients received biologics (45% Infliximab, 29% Adalimumab, 9.7% Vedolizumab, and 8.8% Ustekinumab), 67% salicylates, 47.6% immunosuppressors, and 0.8% Tofacitinib. Of those submitted to surgery (34.1%, n=439), 54% were elective versus 46% urgent; most procedures (80%) were open/laparotomy, while 20% were laparoscopic. Of those, 8.5% were colectomy. The presence of CD, pancolitis, the absence of (isolated) proctitis, younger age (<20 years), rheumatologic manifestations, and no history of smoking were found to be independent risk factors.


This is the first epidemiological study using the national patient registry organized by GEDIIB. The profile of patients with severe disease is consistent with the data in the literature, characterized by younger age, greater extent of disease, and extraintestinal manifestations. Further epidemiological studies should be encouraged to guide national policies aimed at the early diagnosis and treatment of IBD.